Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models by Yiqing Qu et al.
Qu et al. Journal of Experimental & Clinical Cancer Research 2014, 33:52
http://www.jeccr.com/content/33/1/52RESEARCH Open AccessAntitumor activity of selective MEK1/2 inhibitor
AZD6244 in combination with PI3K/mTOR
inhibitor BEZ235 in gefitinib-resistant NSCLC
xenograft models
Yiqing Qu*, Xiuxiu Wu, Yunhong Yin, Yan Yang, Dedong Ma and Hao LiAbstract
Purpose: Although the EGF receptor tyrosine kinase inhibitors (EGFR-TKI) gefitinib have shown dramatic effects
against EGFR mutant lung cancer, patients become resistant by various mechanisms, including gatekeeper
EGFR-T790M mutation, MET amplification, and KRAS mutation, thereafter relapsing. AZD6244 is a potent, selective,
and orally available MEK1/2 inhibitor. In this study, we evaluated the therapeutic efficacy of AZD6244 alone or with
BEZ235, an orally available potent inhibitor of phosphatidylinositol 3–kinase (PI3K) and mammalian target of
rapamycin (mTOR), in gefitinib-resistant non-small cell lung carcinoma (NSCLC) models.
Experimental design: NCI-H1975 with EGFR-T790M mutation, NCI-H1993 with MET amplification and NCI-H460 with
KRAS/PIK3CA mutation human NSCLC cells were subcutaneous injected into the athymic nude mice respectively.
Mice were randomly assigned to treatment with AZD6244, BEZ235, AZD6244 plus BEZ235, or control for 3 weeks,
then all mice were sacrificed and tumor tissues were subjected to western blot analyses and immunohistochemical
staining.
Results: AZD6244 could inhibit the tumor growth of NCI-H1993, but slightly inhibit the tumor growth of NCI-1975
and NCI-H460. Combining AZD6244 with BEZ235 markedly enhanced their antitumor effects and without any
marked adverse events. Western blot analysis and immunohistochemical staining revealed that AZD6244 alone
reduced ERK1/2 phosphorylation, angiogenesis, and tumor cell proliferation. Moreover, MEK1/2 inhibition resulted
in decreased AKT phosphorylation in NCI-H1993 tumor model. BEZ235 also inhibited AKT phosphorylation as well
as their downstream molecules in all three tumor models. The antiangiogenic effects were substantially enhanced
when the agents were combined, which may due to the reduced expression of matrix metallopeptidase-9 in
tumor tissues (MMP-9).
Conclusions: In this study, we evaluated therapy directed against MEK and PI3K/mTOR in distinct gefitinib-resistant
NSCLC xenograft models. Combining AZD6244 with BEZ235 enhanced their antitumor and antiangiogenic effects.
We concluded that the combination of a selective MEK inhibitor and a PI3K/mTOR inhibitor was effective in suppressing
the growth of gefitinib-resistant tumors caused by EGFR T790M mutation, MET amplification, and KRAS/PIK3CA mutation.
This new therapeutic strategy may be a practical approach in the treatment of these patients.
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Lung cancer is the leading cause of cancer-related death
in many countries, including the China [1]. Non-small
cell lung cancer (NSCLC) accounts for up to 80% of all
lung cancer cases; patients typically present with ad-
vanced disease at the time of diagnosis. The prognosis of
patients with advanced lung cancer remains poor, and
recent studies show that conventional therapies may
have reached a therapeutic plateau as evidenced by the
5-year survival rate for NSCLCs, which remains at
15% [2,3]. The EGF receptor tyrosine kinase inhibitors
(EGFR-TKIs) gefitinib and erlotinib have shown marked
therapeutic effects against NSCLCs with EGFR activating
mutations, such as exon 19 deletions and L858R point mu-
tations [4]. Almost all tumors, however, acquire resistance
to EGFR-TKIs after varying periods of time. Common
mechanisms for acquired resistance include emergence of
an EGFR gatekeeper mutation (T790M) and MET gene
amplification [5,6]. In addition, PIK3CA mutations as
well as KRAS mutations have been found to contribute to
EGFR-TKIs resistance in a subpopulation of tumors [7,8].
The limited therapeutic options currently available for
patients with advanced lung cancer create a pressing
need to identify new therapeutic strategy.
Selumetinib (AZD6244) is an oral, non-ATP competi-
tive inhibitor and highly specific for extracellular signal-
regulated kinase (ERK) kinase (MEK)1/2, a key enzyme
in the RAS-RAF-MEK-ERK pathway. AZD6244 had
minimal effects on the p38, c-Jun-NH2-kinase, PI3K,
and MEK5/ERK5 pathways and is currently in phase II
clinical trial in KRAS-mutant NSCLC [9,10]. In vivo,
AZD6244 could inhibit the tumor growth in HT-29
xenograft model, which is a colorectal tumor model car-
rying a BRAF mutation, at a dose of 100 mg/kg and the
tumor growth inhibition of AZD6244 is better than gem-
citabine [11]. However, the inhibition of MEK signaling
alone may not be sufficient in patients with gefitinib-
resistant NSCLC, and negative feedback mechanisms in
PI3K pathway may be problematic when it is used alone
[12]. By contrast, combined blockade of both pathways
was able to overcome the reciprocal pathway activation
induced by inhibitor-mediated release of negative feed-
back loops and resulted in a significant tumor growth in-
hibition. Thus, coinhibition of both pathways has shown
use in reducing tumor growth in a variety of xenograft
models [13,14], and clinical trials of such combinations
are under way in adults.
BEZ235 is an orally available dual inhibitor of PI3K
and mTOR that is being evaluated in phase I/II trials
[15]. With the aim of developing effective therapeutic
strategy for treatment gefitinib-resistant NSCLCs, we have
initially evaluated the antitumor activity of AZD6244
alone or combination with BEZ235 in a panel of three hu-
man NSCLC cell lines, which were selected according totheir different mutation status for EGFR-T790M, MET
and KRAS/PIK3CA genes. We hypothesized that tar-
geting the MEK pathway in combination with selective
inhibitors of PI3K/mTOR signaling, could overcome




AZD6244 and BEZ235 were purchased from Sellech
Chemicals (Houston, TX, USA), all drugs were dis-
solved in sterile dimethylsulfoxide (DMSO) and a 10 mM
working solution was prepared and stored in aliquots
at −22°C. Working concentrations were diluted in culture
medium just before each experiment. RPMI1640 media
and fetal bovine serum (FBS) were purchased from Invi-
trogen (Carlsbad, CA, USA). Fibronectin and 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) were obtained from Sigma (St. Louis, MO, USA).
Phospho-AKT (Ser473, p-AKT), phospho-S6 (Ser240/244,
p-S6), phospho-4E-BP1 (Ser 65, p-4E-BP1), phospho-
ERK1/2 (Thr202/Tyr204, p-ERK1/2), phospho-MEK1/2
(Ser217/221, p-MEK1/2), AKT, S6, 4E-BP1, MEK1/2 and
ERK1/2 antibodies were purchased from Santa Cruz
Biotechnology, Inc (Santa Cruz, CA, USA). CD31 and
Ki-67 antibodies for IHC were purchased from Cell Sig-
naling Technology (Danvers, MA, USA). All other chemi-
cals used in this study were of analytical reagent grade.
Cell lines
The NCI-H1975 EGFR T790M mutation [16], NCI-H460
KRAS/PIK3CA mutation and NCI-H1993 MET amplifica-
tion [17,18] human NSCLC cell lines were obtained from
American Type Culture Collection (ATCC) (Manassas,
VA, USA). The cells were cultured in RPMI1640 medium
supplemented with 10% FBS, 100 mg/L streptomycin,
100 IU/mL penicillin and 0.03% L-glutamine (Hyclone,
Logan, UT, USA) and maintained at 37°C with 5% CO2
in a humidified atmosphere.
Cell viability assay
Cell viability was measured using the MTT [3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyl tetrazolium] dye reduc-
tion method. Tumor cells (1 × 104 cells/100 mL/well) in
RPMI1640 medium with 10% FBS were plated into 96-
well plates and cultured with indicated compounds for
72 h, followed by the addition of 50 mL of MTT solution
(2 mg/mL; Sigma, St. Louis, MO) to each well and fur-
ther incubation for 2 h. The medium was removed, and
the dark blue crystals in each well were dissolved in
100 mL dimethyl sulfoxide. The absorbance of the wells
was measured with a microplate reader at test and
reference wavelengths of 490 nm, respectively. Percent
growth was reported relative to untreated controls. Each
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performed at least three times.
Efficacy study in vivo
BALB/C nude mice (female, 6-7 weeks old) were ob-
tained from Vital River (Beijing, China). Mice were
maintained under super pathogen-free conditions and
housed in barrier facilities on a 12-h light/dark cycle,
with food and water ad libitum. All animal experiments
were performed in accordance with protocols approved
by the Shandong University Experimental Animal Care
and Use Committee. Mice were injected subcutaneous
(s.c.) with 5 × 106 NCI-H1993, NCI-H1975 and NCI-
H460 cells that had been resuspended in 200 μL of
matrigel (BD Biosciences, Milan, IT). AZD6244, solubi-
lized in a methocel/polysorbate buffer, was injected
by oral gavage twice daily at the dose of 25 mg/kg
for 3 weeks [19]. BEZ235, was reconstituted in NMP
(1-methyl-2 pyrrolidone) and PEG300, and injected by
oral gavage once daily at the dose of 20 mg/kg for 3 weeks
[20]. When the mean volumes of tumors were between
150 and 200 mm3, mice were randomly divided in
four groups (ten mice per group). The tumor volume
and body weight in each group were balanced. The
animals were ear-punched for identification during the
study. Two orthogonal diameters of the tumor are mea-
sured with digital vernier calipers and individual animal
weights were weighed and recorded twice a week. Tumor
volume (TV) are measured and recorded during treatment
period by the formula: TV = Length ×Width2/2. Growth
inhibition from the start of treatment was assessed by
comparison of the differences in tumor volume between
control and treated groups. Tumor growth inhibition T/C
ratio is calculated by the following equations: T/C ratio =
(Vt −V0)Compound treated/(Vt −V0)Control × 100 %.
Western blot analysis
The expressions of, p-ERK1/2, p-AKT, p-S6, p-MEK1/2
and p-4E-BP1 in tumor tissues were examined by West-
ern Blotting. Fresh tumors in each group were resected
after last treatment with AZD6244 and/or BEZ235 for
2 h on Day 21 of the efficacy study. Tumor tissues were
lysed by lysis buffer (50 mM HEPES [pH 7.4], 150 mM
NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2,
1 mM EDTA [pH 8.0], 100 mM NaF, 1 mM phenylmethyl-
sulfonyl fluoride 1 mM sodium orthovanadate, 10 μg/mL
aprotinin, 50 μg/mL leupeptin, and 1 μg/mL pepstatin A).
The resected tumor samples were homogenized with
lysis buffer containing 25 mM b-glycerophosphate and
0.5% (v / v) phosphatase inhibitor cocktail 2 (Sigma-
Aldrich, St. Louis, MO, USA) at 4°C. Cellular debris was
removed by centrifugation at 17 860 g for 20 min at 4°C.
Aliquots of the supernatants containing 5–20 μg of protein
were subjected to SDS-PAGE under reducing conditions.The protein concentration of the supernatant was deter-
mined by Bio-Rad protein assay reagent (Bio-Rad, CA,
USA). Equal amounts of protein were separated by sodium
dodecyl sulfate/polyacrylamidegel electrophoresis (SDS/
PAGE) on 10% gels, blotted on polyvinylidene difluor-
ide (PVDF), and probed with p-ERK1/2, p-AKT, p-S6,
p-MEK1/2, p-4E-BP1, MMP2, MMP9, ERK1/2, AKT, S6,
MEK1/2 and 4E-BP1 rabbit monoclonal antibody and
subsequently with goatanti-rabbit (HRP), and detected by
chemiluminescence. To measure protein loading, anti-
bodies directed against β-actin were used.
Immunohistochemical analysis
Fresh tumors in each group were resected after last
treatment with AZD6244 and/or BEZ235 for 2 h on Day
21 of the efficacy study, fixing in formalin and em-
bedding the tumor tissue. Cutting and mounting the
section. Immunocytochemical analysis was performed
according to the method described on the commercial
kits to examine the expressions of CD31 and Ki-67 (Cell
Signaling Technology, Danvers, MA, USA).
Caspase activity assay
The apoptotic markers, activity of caspase-3,-8 and −9
were measured by using caspase colorimetric protease
kits (Abnova, Walnut, CA, USA). Fresh tumors in each
group were resected after last treatment with AZD6244
and/or BEZ235 for 2 h on Day 21 of the efficacy study,
and then tumor lysis containing 200 μg of protein was
incubated with 5 μL of 4 mM pNA-conjugated substrate
(DEVD-pNA, IETD-pNA and LEHD-pNA) at 37°C for
2 h. The amount of pNA released was measured at
405 nm using a microplate reader.
Statistical analysis of the data
All results and data were confirmed in at least three sep-
arate experiments. Data are expressed as means ± SD,
and were analyzed by ANOVA using Statistics Package
for Social Science (SPSS) software (version 13.0; SPSS,
Chicago, IL, USA). Test article can be demonstrated as
an effective compound until T/C ratio ≤ 42% and a value
of P < 0.05 was indicated to be statistically significance
on tumor volume calculation.
Results
Effect of AZD6244 and BEZ235 on viability of
gefitinib-resistant NSCLC in vitro
Before evaluating the effect of AZD6244, BEZ235 and
AZD6244 plus BEZ235 treatment on gefitinib-resistant
NSCLC xenograft models in nude mice, the sensitivity
of cell lines to compounds was evaluated in vitro. Cell
proliferation was analyzed by MTT assay in cells treated
with 0, 0.01, 0.1, 1, 10 and 100 μM of AZD6244 or
BEZ235 for 72 h. The results showed that AZD6244
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a low micromolar IC50 value of 5.6 μM (Figure 1A).
Moreover, AZD6244 alone mildly inhibited cell growth
with IC50 values of 37.5 μM and 26.8 μM in NCI-H1975
and NCI-H460 cells, respectively (Figure 1A). BEZ235
alone also suppressed the growth of three cell lines with
slightly high IC50 values of 23.5, 67.8 and 16.8 μM in
NCI-H1993, NCI-H1975 and NCI-H460 cells, respect-
ively (Figure 1B).
Concurrent inhibition of MEK and PI3K/mTOR has a
synergistic effect on gefitinib-resistant NSCLC cell lines
growth in vitro
The anti-proliferative effect of combining a MEK and
PI3K/mTOR inhibitor was measured in NCI-H1993,
NCI-H1975 and NCI-H460 cells by calculating the com-
bination index (CI) according to the Chou-Talalay
method [21] using a fixed dose ratio. Both AZD6244
and BEZ235 were introduced to cell cultures at 0.25×,
0.5×, 1×, 2× and 4× their respective IC50s in NCI-
H1993, NCI-H1975 and NCI-H460 cell lines for 72 h.
Cell growth in all cell lines was markedly decreasedFigure 1 Anti-proliferative effects of AZD6244 and BEZ235 in
NCI-H1993, NCI-H1975 and NCI-H460 gefitinib-resistant cell
lines. Cells were treated with varying concentrations of AZD6244
(A) or BEZ235 (B) alone for 72 h. Doses ranged from 0.01 μM to
100 μM. Mean ± SD, n = 5.following combination treatment at multiple paired con-
centrations when compared with either single agent
alone. The cells viability data were processed to get the
CI under the corresponding effective dose (ED) in NCI-
H1993, NCI-H1975 and NCI-H460 cell lines (Figure 2)
by CalcuSyn software. For the NCI-H1993 cell line the
following CI value was obtained: 0.4101 (ED50). For NCI-
H1975 and NCI-H460 cell line the CI values were 0.02052
(ED50), and 0.0440 (ED50) respectively. The CI results
suggested that AZD6244 and BEZ235 worked synergistic-
ally to produce an anti-proliferative effect in NCI-H1993,
NCI-H1975 and NCI-H460 cell lines (Figures 2A-C).
Tumor growth inhibition effect of MEK and PI3K/mTOR
inhibitors in gefitinib-resistant NSCLC tumor models
In order to investigate tumor growth inhibition effect of
AZD6244 and/or BEZ235 in vivo, we used AZD6244,Figure 2 Synergistic effects of AZD6244-BEZ235 combination
therapy on cell viability. NCI-H1993 (A), NCI-H1975 (B) and NCI-H460
(C) cells were treated with AZD6244 alone, BEZ235 alone or
AZD6244-BEZ235 in combination for 72 h. Results were analyzed
according to the Chou-Talalay method [19]. The combination index (CI)
values were calculated by using CalcuSyn software. Mean ± SD, n = 5.
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H1993, NCI-H1975 and NCI-H460 subcutaneous tumor
models respectively for 3 weeks. As shown in Figure 3A-C,
treatment with AZD6244 for 3 weeks was able to in-
hibit tumor growth of NCI-H1993 (T/C value 40%), but
slightly inhibit tumor growth in both NCI-H1975 andFigure 3 Antitumor activity of AZD6244 and/or BEZ235 in
mouse xenograft models of human tumors. Nude mice-bearing
NCI-H1993 (A), NCI-H1975 (B), and NCI-H460 (C) tumors were
administered 25 mg/kg AZD6244 twice daily and/or 20 mg/kg
BEZ235 once daily up to 21 days. Tumors were resected from nude
mice on day 21 (D). Tumor volume was measured using calipers on
the indicated days. Mean ± SD, n = 10. *, P < 0.05 vs control group.
**, P < 0.01 vs control group.NCI-H460 subcutaneous tumor models (T/C values
60% and 65%), whereas BEZ235 treatment caused an
approximately 50% reduction in tumor growth in all
three subcutaneous tumor models. In contrast, the com-
bined treatments with the two drugs almost completelyFigure 4 Changes in body weight of mice treated with control
group or AZD6244 and/or BEZ235. Nude mice-bearing NCI-H1993 (A),
NCI-H1975 (B), and NCI-H460 (C) tumors were administered 25 mg/kg
AZD6244 twice daily and/or 20 mg/kg BEZ235 once daily up to 21 days.
Body weight was measured on the indicated days. Mean ± SD, n = 10.
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growth at the end of the 3 weeks of therapy (Figure 3A-D).
Single agent and combination treatment protocols were
well tolerated by mice, with no weight loss or other signs
of acute or delayed toxicity (Figure 4A-C).
Effect of MEK and PIK3/mTOR inhibitors on signaling
transduction pathways in gefitinib-resistant NSCLC
tumor models
To assess the impact of both compounds on down-
stream molecules of the MEK and PI3K pathways, we
used Western blot analysis to observe phosphorylation
status and total protein expression in tumor tissues. The
results showed that p-MEK1/2, p-ERK1/2, p-AKT, p-S6
and p-4E-BP1 appeared to be inhibited by AZD6244 and
BEZ235 combination treatment, whereas the total pro-
tein levels of MEK1/2, ERK1/2, AKT, S6 and 4E-BP1
remained unchanged in each tumor model (Figure 5).
Western blot analysis of downstream signals also showed
treatment with AZD6244 or BEZ235 inhibited the phos-
phorylation of ERK1/2 or AKT in all three tumor
models respectively. In addition, combined treatment
with AZD6244 and BEZ235 showed greater inhibition of
p-ERK1/2 and p-AKT than observed in control group or
mice treated with each compound alone in vivo (Figure 5).
Interestingly, the impact from both inhibitors on p-S6
and p-4E-BP1 levels was, alternatively, tumor model spe-
cific. For example, AZD6244 and BEZ235 alone and in
combination markedly inhibited p-S6 and p-4E-BP1 ex-
pression levels in NCI-H1993 tumor models, compared
with the minimal suppression observed in NCI-H460
tumor model (Figure 5). Neither AZD6244 nor BEZ235
alone suppressed p-S6 and p-4E-BP1 in NCI-H1975Figure 5 Effects of AZD6244-BEZ235 combination therapy on PI3K/AKT
models were treated with the AZD6244 and/or BEZ235 for 2 h on Day 21 of t
(S473)/AKT, p-ERK (T202/Y204)/ERK, p-S6 (S240/244)/S6 and p-4E-BP1 (S65)/4E-tumor model. We also found that the expression of
MMP-9 was significantly inhibited by AZD6244 and
BEZ235 combination treatment, whereas the expres-
sion of MMP-2 was not affected by the treatment.
Effect of MEK and PIK3/mTOR inhibitors on the
expressions of Ki-67 and CD31 in gefitinib-resistant
NSCLC tumor models
To characterize the mechanism of tumor growth inhib-
ition observed in our gefitinib-resistant NSCLC tumor
models by AZD6244 and BEZ235, lung tumor tissues were
assessed by evaluating Ki-67 expression using immunohis-
tochemical analyses. We observed active cell prolifer-
ation in NCI-H1993 tumor model, with a 56% proliferation
index (Figure 6A). Monotherapy with AZD6244 or
BEZ235 slightly decreased the percentage of Ki-67-positive
proliferating tumor tissues, with proliferation indices of
42% and 39%, respectively (Figure 6A). Combined treat-
ment with AZD6244 and BEZ235 markedly decreased the
percentage of Ki-67-positive proliferating tumor tissues to
10%, consistent with the marked inhibition of ERK1/2 and
AKT phosphorylation. We also found the similar results in
NCI-H1975 and NCI-H460 tumor models (Figure 6A).
To evaluate the potential antiangiogenic mechanism
of AZD6244 and BEZ235, gefitinib-resistant NSCLC
tumor tissues were analyzed by immunostaining for CD31
(platelet endothelial cell adhesion molecule 1). The results
showed BEZ235 significantly decreased the vascular dens-
ity of all three gefitinib-resistant NSCLC tumors, whereas
AZD6244 monotherapy had only a mildly effect upon lung
tumor angiogenesis. The antiangiogenic effects AZD6244
and BEZ235 were markedly increased when they were
combined (Figure 6B).and MEK/ERK pathways. All three gefitinib-resistant tumor xenograft
he efficacy study, tumor tissues were then harvested to detect p-AKT
BP1.
Figure 6 Effects of AZD6244 and/or BEZ235 on the expressions of Ki-67 (A) and CD31 (B) in NCI-1993, NCI-1975 and NCI-H460
xenograft models. All three gefitinib-resistant tumor xenograft models were treated with the AZD6244 and/or BEZ235 for 2 h on Day 21
of the efficacy study, tumor tissues in each group were resected and immunostained with anti-Ki67 and anti-CD31 antibodies. N = 10, *, P < 0.05 vs
vehicle group. **, P < 0.01 vs vehicle group.
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caspase-3, 8 and 9 activities in gefitinib-resistant
NSCLC tumor models
In order to investigate whether AZD6244 and/or BEZ235
would induce apoptosis in gefitinib-resistant NSCLC
tumor models, activity of caspase-3, 8 and 9 were mea-
sured by the colorimetric assay. The results showed that
AZD6244 and/or BEZ235 had no effect on caspase-3,
8 and 9 activities in all three gefitinib-resistant NSCLC
tumor models (Figure 7).Discussion
Although advances have been made in cancer treatment
with the development of selective molecular targeted
therapies, several relevant issues for their optimal and
effective use remain unsolved. Recent studies have
demonstrated that the EGFR-TKI gefitinib and erloti-
nib are associated with a high response rate and prolong
progression-free survival in patients with EGFR mutant
lung cancer [22]. Responders to these agents, however,
later relapse after acquiring EGFR-TKI resistance, making
Figure 7 Effects of AZD6244 and/or BEZ235 on the activities of
caspase-3, 8 and 9 in NCI-1993, NCI-1975 and NCI-H460
xenograft models. All three gefitinib-resistant tumor xenograft
models were treated with the AZD6244 and/or BEZ235 for 2 h on
Day 21 of the efficacy study, tumor tissues in each group were
resected and measured by caspase colorimetric protease kits. N = 10.
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overcome acquired resistance to EGFR-TKI. Current
clinical approaches to combat resistance in lung adeno-
carcinoma include irreversible and mutant-selective in-
hibitors of EGFR, combination of cetuximab and afatinib
[23] and combination of an EGFR inhibitor with a drug
targeting a resistance pathway, such as the combination
of gefitinib and a MET inhibitor [24]. However, alterna-
tive RTK pathways that are activated following EGFR
inhibition are another area for investigation. These alter-
native pathways may bypass or evade inhibition of EGFRsignaling, thereby enabling combinations of agents to
simultaneously attack multiple molecular targets for
cancer growth inhibition. One potential solution to
overcome multiple mechanisms of resistance is to tar-
get downstream pathways. In this study, we show that
the combination of a selective MEK inhibitor and a
PI3K/mTOR inhibitor is effective against tumor cell
lines refractory to gefitinib by three different mecha-
nisms: an EGFR gatekeeper T790M mutation, MET
amplification, and KRAS/PIK3CA mutation. To our
knowledge, this is the first report of the effects of MEK
TKI with PI3K/mTOR TKI therapy in gefitinib-resistant
models of NSCLC.
MEK is a potentially relevant molecular therapeutic
target since it is the activated downstream of the axis
RAS/RAF proteins and in turn activates ERK to induce
cell proliferation. Therefore, several selective MEK in-
hibitors have been developed [25] and more than ten
MEK inhibitors have entered early clinical trial evalu-
ation [26]. Unfortunately, clinical activity as single agent
has been rarely observed with MEK inhibitors in gefitinib-
resistant NSCLC patients [27]. The benefit of blocking an
individual pathway has been largely limited by the pres-
ence of a compensatory feedback loop between PI3K and
MEK. For example, inhibition of the MEK pathway results
in activation of the PI3K pathway [28], and PI3K activation
mediates resistance to MEK inhibition [29]. In our study,
in order to circumvent this compensatory feedback, con-
current blockade of the two pathways has been tested, and
synergy in antitumor effects was detected, providing the
rationale for phase I clinical trials. Moreover, early signs of
clinical benefit have been reported in advanced cancer by
a retrospective analysis on patients receiving agents that
target both pathways [30].
Gatekeeper mutations, the T790M mutation in EGFR
associated with resistance to gefitinib [31], are common
mechanisms by which tumor cells acquire resistance to
molecularly targeted drugs. Although irreversible EGFR-
TKIs, including BIBW2992, have been developed to
overcome T790M-mediated resistance to gefitinib [32], re-
cent clinical trials have failed to show that monotherapy
with irreversible EGFR-TKIs has benefits in patients with
NSCLC refractory to gefitinib [33]. This may be due, at
least in part, to the low selectivity of this class of com-
pounds to wild-type and mutant EGFR. In addition, be-
cause HGF overexpression was frequently observed in
tumors with the gatekeeper T790M mutation [34], mono-
therapy with a mutant-selective EGFR-TKI may not be
sufficient to inhibit the growth of tumors with acquired
resistance to gefitinib. Our findings suggest that the com-
bination of a MEK-TKI and a PIK3/mTOR-TKI may be ef-
fective in controlling these resistant tumors.
Many KRAS-mutant cancer cells have been shown to
be sensitive to MEK inhibitors, [35] and KRAS mutations
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upon histology and ethnicity [36-38], suggesting that a
subset of lung cancers would likely be highly sensitive to
AZD6244. Our finding that AZD6244 was effective in
one distinct KRAS mutant human lung cancer NCI-H460
models supports and validates this hypothesis. Although
monotherapy with AZD6244 resulted in antitumor and
some antiangiogenic effects in all of our lung cancer
models, the antitumor effects were more apparent in the
NCI-H1993 lung adenocarcinoma model. The increased
antitumor efficacy observed in this model is associated
with differences in the inhibitory effect of p-AKT signal-
ing pathway in NCI-H1975 and NCI-H460 lung tumors.
However, additional studies are needed to elucidate this
phenomenon.
In this study, we evaluated therapy directed against
MEK and PI3K/mTOR in distinct gefitinib-resistant
NSCLC xenograft models. MEK or PI3K/mTOR inhib-
ition resulted in antitumor effects for these gefitinib-
resistance NSCLC models by blocking key intracellular
pathways controlling cell proliferation and survival as
demonstrated both in vitro and in vivo. Surprisingly,
PI3K/mTOR inhibition by BEZ235 also suppressed lung
tumor angiogenesis and targeted both MEK and PI3K/
mTOR activation in lung tumors, resulting in substantial
antiangiogenic effects, which may due to the significantly
reduced expression of MMP-9 in tumors. We concluded
that the combination of a selective MEK inhibitor and a
PI3K/mTOR inhibitor was effective in suppressing the
growth of gefitinib-resistant tumors caused by EGFR
T790M mutation, MET amplification, and KRAS/PIK3CA
mutation. These findings represent a promising strategy
for the treatment of gefitinib-resistant NSCLC and pro-
vide a strong basis for the design of clinical trials for this
purpose.
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